Andrew J. Plodkowski

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt et al. · Cancer Discovery · 2018 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +16

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Hira Rizvi, Francisco Sánchez-Vega, Konnor La et al. · Journal of Clinical Oncology · 2018 · 1.4K citations · Full text

Medicine, Immunology, Oncology +17

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

Kathryn C. Arbour, Laura Mezquita, Niamh M. Long et al. · Journal of Clinical Oncology · 2018 · 1.1K citations · Full text

Pharmacy, Oncology, Pharmacology +17

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

Lisa Derosa, Matthew D. Hellmann, Marco Spaziano et al. · Annals of Oncology · 2018 · 871 citations · Full text

Medicine, Immunology, Oncology +17

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

Alexander Drilon, Natasha Rekhtman, Maria E. Arcila et al. · The Lancet Oncology · 2016 · 482 citations · Full text

Medicine, Oncology, Pharmacology +13